medicalxpress.com
Microbiome shift linked to Crohn's disease remission sparks clinical study on new therapy
This reports a potential new way to extend remission after exclusive enteral nutrition by combining diet with fecal microbiome transfer—an approach that targets the gut microbiome rather than adding drugs. If effective, it could offer a non-pharmacologic option to help maintain quiescent Crohn's disease.
People with Crohn's disease (adults and children), caregivers, gastroenterology clinicians, and researchers interested in microbiome therapies and dietary treatment approaches.
What To Know
Researchers found that exclusive enteral nutrition (EEN) prompts changes in the gut microbiome—particularly growth of bacteria influenced by medium-chain fatty acids—that appear to reduce inflammation in models.
Based on these findings, a clinical study is testing whether combining EEN with fecal microbiome transfer (fecal transplant capsules from screened healthy donors) can prolong remission in people with Crohn's disease.
The study group at Technical University of Munich and LMU Hospital mapped how a special liquid diet changes patients' stool microbiome and showed in lab and mouse models that a microbiome “pre-adapted” by the formula prevented inflammation.
They are now enrolling a clinical study that gives patients EEN followed by oral fecal microbiome transfer capsules produced at the University Hospital of Cologne. The trial aims to evaluate safety, feasibility, and whether the approach can stabilize or delay recurrence of inflammation.
Practical takeaways: This is an early-stage clinical study testing a diet-plus-microbiome-transfer strategy rather than an established therapy. It does not report human outcomes yet; the article describes preclinical findings and the launch of a trial.
If you’re interested in microbiome-focused treatments or dietary approaches, watch for trial results and speak with your clinical team before changing treatment.
The article describes preclinical and mechanistic work published in Cell Host & Microbe and the start of a clinical study; it does not provide results from human participants yet.
Fecal microbiome transfer is an investigational approach in IBD and has known safety and regulatory considerations; trial outcomes will determine whether this strategy is effective and safe in patients.
